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Abstract  
AIM: Prodynorphin (PDYN; OMIM: 131340) is the precursor of the dynorphin related peptides 
which plays an important role in drug abuse. Previous studies have been shown that the expression 
of PDYN is regulated by a genetic polymorphism of VNTR in the promoter region of the gene.  
MATERIALS AND METHODS: The present case-control study was performed on 52 (41 males, 11 
females) methamphetamine dependence patients and 635 (525 males, 110 females) healthy blood 
donors frequency matched with the patients according to age and gender, as a control group was 
participated in the study.  
RESULTS: The genotypes of VNTR PDYN polymorphism were determined using PCR method. 
The HL (OR = 1.22, 95%CI: 0.67-2.20, P = 0.500) and LL (OR = 0.86, 95%CI: 0.28-2.57, P = 0.792) 
genotypes does not alter the risk of methamphetamine dependence, in comparison with the HH 
genotypes.  
CONCLUSION: The present study revealed no association between the VNTR polymorphism in the 
promoter region of the PDYN gene and methamphetamine dependence risk. 
 
 
 
 
Introduction 
 
Prodynorphin (PDYN; OMIM: 131340) is the 
precursor of the dynorphin related peptides which 
plays an important role in several complex traits such 
as drug abuse [1]. It has been reported that the 
expression level of the PDYN gene is significantly 
increased by cocaine [2]. On the other hand, the Pdyn 
knockout mice showed increased explorative behavior 
in anxiety tests suggesting an anxiogenic role of 
peptides derived from PDYN [3]. The PDYN family of 
neuropeptides comprises six peptides of varying 
lengths that are formed from the precursor PDYN and 
which activate kappa-opioid receptors (KORs) located 
in the peripheral and central nervous systems. The 
functional genetic polymorphisms in the PDYN gene 
may affect the level of transcription, or response to 
environmental or internal stimuli. This would in turn 
result in downstream neurobiological and behavioral 
adaptations (e.g., proximally through dynorphins’ 
agonist actions on KORs). Therefore, genetic 
variations or epigenetic changes of the PDYN could 
underlie vulnerability to drug dependence [4, 5]. 
It is well established that within the core 
promoter region of the PDYN, a 68-bp sequence was 
found to occur as a polymorphic element, either 
singular or as tandemly repeated two, three, four, or 
five times [6, 7]. This genetic polymorphism has an 
important role in regulation of PDYN expression. The 
expression level of PDYN was decreased as a 
function of number of repeats [6, 8].  
Several studies investigated the association 
between the PDYN VNTR polymorphism and 
susceptibility to heroin, cocaine and 
methamphetamine dependence [7, 9-13]. 
Dependence to drugs is a heterogeneous chronic 
multifactorial disease that has major medical, social, 
and economic complications. Identification of the 
genetic polymorphisms may increase our 
understanding of the disorders, help in the 
development of new treatments and advance 
personalized medicine [14]. 
However, there is only published study 
investigating the association between this 
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polymorphism and the risk of methamphetamine 
dependence in Japanese population [13].  
There is no study in Caucasian populations. 
Therefore, the present case-control study was carried 
out. The aim of the present study is to investigate the 
association between PDYN VNTR polymorphism and 
methamphetamine dependence susceptibility. 
 
 
Materials and Methods 
 
A detailed description of the study subjects 
has been reported in our recently published report 
[15]. Briefly, a total of 52 (41 males, 11 females) 
methamphetamine dependence patients and 635 (525 
males, 110 females) healthy blood donors frequency 
matched with the patients according to age and 
gender, as a control group was participated in the 
study. The patients were in methadone maintenance 
for treating methamphetamine dependence and all of 
them reported methamphetamine as their primary 
drug of choice. The mean years (+ SD) of duration of 
drugs used by the patients was 12.0 (+ 8.1). There 
was no significant difference between the gender 
groups for this duration (t = 0.81, df = 50, P = 0.419). 
Control individuals were blood donors, who declared 
that they did not suffer substance abuse. Considering 
the high heterogeneity of the Iranian population [16-
18], the participants were selected from Persian 
Muslims (Caucasians) living in Shiraz (Fars Province, 
southern Iran). Informed consent was obtained from 
each subject before the study, which was approved by 
the institutional review board of our university. 
Peripheral blood samples were collected from 
the participants. Genomic DNA was isolated from 
EDTA treated blood samples. The PCR conditions for 
determining the genotypes of the PDYN VNTR 
polymorphism was the same as that reported 
previously [7]. The following primers were used: 
forward primer 5’-AGC AAT CAG AGG TTG AAG 
TTG GCA GC-3’ and reverse primer 5’-GCA CCA 
GGC GGT TAG GTA GAG TTG TC-3’. The PCR 
conditions consisted of an initial denaturation step of 
94
◦
C for 5min, followed by 30 cycles of 94
◦
C for 30sec, 
62
◦
C for 45sec and 72
◦
C for 45sec, a final extension of 
72
◦
C for 5min. The PCR products were subjected to 
2.5% agarose gel electrophoresis and then visualized 
with a gel imaging system to determine the 
genotypes. Alleles containing 1, 2, 3, 4, or 5 repeats, 
produced PCR amplicons of 379, 447, 515, 583, and 
651 bp, respectively. For quality control, 15% of 
randomly selected samples were repeated to verify 
genotyping results and 100% concordance was found. 
The alleles of the VNTR polymorphism were divided 
into two groups, L and H reflecting the relatively low 
expressed (1-2 repeats) and high expressed (3-5 
repeats) alleles, respectively. 
The associations between the genotypes of 
the study polymorphism and susceptibility to 
methamphetamine dependence were assessed by 
calculating odds ratios (ORs) and 95% confidence 
intervals (CIs). The reference group consisted of 
individuals with HH genotypes. Statistical analyses 
were performed using the SPSS version 11.5 
statistical software package (SPSS Inc, Chicago, IL, 
USA). A probability of P<0.05 was considered 
statistically significant. All P values were two-tailed.  
 
 
Results and Discussion 
 
Table 1 shows the genotype distribution of the 
VNTR polymorphism between the cases and controls. 
Considering that there was no significant difference 
between gender groups for the genotypes (For 
patients: 
2 
= 0.53, df = 2, P = 0.764; For controls 
2 
= 
0.13, df = 2, P = 0.935), the gender groups were 
pooled. Table 2 shows the distribution of the 
genotypes according the L and H allele groups. The 
genotypic frequencies of the polymorphism in controls 
(
2 
= 0.61, df = 1, P = 0.432) and patients (
2 
= 0.36, 
df = 1, P = 0.547) were consistent with the Hardy-
Weinberg equilibrium distribution. 
Table 1: Genotypic distribution of PDYN VNTR polymorphism 
in control and methamphetamine dependence cases 
Genotypes Controls Cases 
1/1 1 0 
1/2 5 0 
1/3 5 0 
2/2 55 4 
2/3 242 24 
2/4 11 0 
3/3 292 21 
3/4 22 2 
3/5 1 1 
4/4 1 0 
 
Statistical analysis indicating that the HL (OR 
= 1.22, 95%CI: 0.67-2.20, P = 0.500) and LL (OR = 
0.86, 95%CI: 0.28-2.57, P = 0.792) genotypes does 
not alter the risk of methamphetamine dependence, in 
comparison with the HH genotypes (Table 2). There is 
no significant interaction between gender and 
genotypes for alter the risk of dependency (P = 
0.839). Also there is no association between allelic 
prevalence and methamphetamine dependence risk 
(OR=1.04, 95%CI: 0.67-1.61, P=0.856).   
Few studies investigated the association 
between risk of heroin dependence and PDYN VNTR 
polymorphism with inconsistent results [6, 7, 9-13]. A 
significant association was reported between the 
PDYN VNTR polymorphism and methamphetamine 
dependence in Japan; alleles with three or four copies 
of the 68-bp repeat were found more frequently in 
Japanese individuals with methamphetamine 
dependence compared to healthy control group [13].   
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Table 2: Association between PDYN VNTR polymorphism and 
risk of methamphetamine dependence 
Genotypes/ Alleles Controls 
N (%) 
Cases 
N (%) 
 OR 95% CI P-Value 
HH 316 (49.8) 24 (46.2)  1.0 - - 
HL 258 (40.6) 24 (46.2)  1.22 0.67-2.20 0.500 
LL 61 (9.6) 4 (7.6)  0.86 0.28-2.57 0.792 
       
Alleles       
H 890 (70.0) 72 (69.2)  1.0 - - 
L 380 (30.0) 32 (30.8)  1.04 0.67-1.61 0.856 
 
Association studies in complex disorders such 
as dependency to a drug are challenging. The 
inconsistency between our present study and previous 
study [13] investigating the association between 
PDYN VNTR polymorphism and risk of dependency to 
methamphetamine may be explained by several 
factors, including small sample size of the studies, 
inadequate statistics, ethnic heterogeneity and 
population stratification, large phenotype range, and 
different diagnostic criteria. 
It should be mentioned that the main limitation 
of the present study is its sample size, especially drug 
abuse patient. Finally, considering the fact that 
ethnicity may influence the observed associations in 
multifactorial diseases [19], replication of this study in 
other countries is recommended. 
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